| In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen P Correale, C Nieroda, S Zaremba, M Zhu, J Schlom, KY Tsang, ... Journal of the National Cancer Institute 89 (4), 293-300, 1997 | 335 | 1997 |
| Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ... Journal of immunotherapy 33 (4), 435-441, 2010 | 249 | 2010 |
| Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin … P Correale, MG Cusi, KY Tsang, MT Del Vecchio, S Marsili, ML Placa, ... Journal of Clinical Oncology 23 (35), 8950-8958, 2005 | 201 | 2005 |
| Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide P Correale, K Walmsley, S Zaremba, MZ Zhu, J Schlom, KY Tsang The Journal of Immunology 161 (6), 3186-3194, 1998 | 182 | 1998 |
| Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials D Ciliberto, C Botta, P Correale, M Rossi, M Caraglia, P Tassone, ... European journal of cancer 49 (3), 593-603, 2013 | 169 | 2013 |
| Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma R Petrioli, A Coratti, P Correale, C D’Aniello, L Grimaldi, G Tanzini, ... American journal of clinical oncology 25 (5), 468-473, 2002 | 132 | 2002 |
| Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients C Botta, V Barbieri, D Ciliberto, A Rossi, D Rocco, R Addeo, N Staropoli, ... Cancer biology & therapy 14 (6), 469-475, 2013 | 108 | 2013 |
| HLA-B* 44 and C* 01 prevalence correlates with Covid19 spreading across Italy P Correale, L Mutti, F Pentimalli, G Baglio, RE Saladino, P Sileri, ... International journal of molecular sciences 21 (15), 5205, 2020 | 98 | 2020 |
| Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony … P Correale, P Tagliaferri, A Fioravanti, MT Del Vecchio, C Remondo, ... Clinical Cancer Research 14 (13), 4192-4199, 2008 | 97 | 2008 |
| Treatment of colon and breast carcinoma cells with 5‐fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA‐A (*) 02.01 restricted, CEA‐peptide … P Correale, A Aquino, A Giuliani, M Pellegrini, L Micheli, MG Cusi, ... International journal of cancer 104 (4), 437-445, 2003 | 97 | 2003 |
| Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma P Correale, MS Rotundo, C Botta, MT Del Vecchio, C Ginanneschi, ... Clinical cancer research 18 (3), 850-857, 2012 | 96 | 2012 |
| Cetuximab±chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell … P Correale, C Botta, MG Cusi, MT Del Vecchio, MM De Santi, ... International journal of cancer 130 (7), 1577-1589, 2012 | 95 | 2012 |
| Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5 … P Correale, MG Cusi, MT Del Vecchio, A Aquino, S Prete, KY Tsang, ... The Journal of Immunology 175 (2), 820-828, 2005 | 94 | 2005 |
| Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell … P Correale, M Marra, C Remondo, C Migali, G Misso, FP Arcuri, ... European journal of cancer 46 (9), 1703-1711, 2010 | 88 | 2010 |
| Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. KY Tsang, M Zhu, CA Nieroda, P Correale, S Zaremba, JM Hamilton, ... Clinical cancer research: an official journal of the American Association …, 1997 | 86 | 1997 |
| Efficient delivery of DNA to dendritic cells mediated by influenza virosomes MG Cusi, C Terrosi, GG Savellini, G Di Genova, R Zurbriggen, P Correale Vaccine 22 (5-6), 735-739, 2004 | 84 | 2004 |
| Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I PK Wallace, KY Tsang, J Goldstein, P Correale, TM Jarry, J Schlom, ... Journal of immunological methods 248 (1-2), 183-194, 2001 | 84 | 2001 |
| Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities C Botta, A Gullà, P Correale, P Tagliaferri, P Tassone Frontiers in oncology 4, 348, 2014 | 79 | 2014 |
| Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse V Nardone, C Botta, M Caraglia, EC Martino, MR Ambrosio, T Carfagno, ... Cancer biology & therapy 17 (11), 1213-1220, 2016 | 76 | 2016 |
| Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients EC Martino, G Misso, P Pastina, S Costantini, F Vanni, C Gandolfo, ... Cell death discovery 2 (1), 1-8, 2016 | 76 | 2016 |
Pierosandro Tagliaferriprofessore di oncologia medica Università magna graecia di CatanzaroDirección de correo verificada de unicz.it
